Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

被引：8
|
作者：
Claudiani, Simone [1 ,2 ]
Apperley, Jane F. [1 ,2 ]
Khan, Afzal [2 ]
Khorashad, Jamshid [2 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Imperial Coll London, Hammersmith Hosp, Dept Immun & Inflammat, Ctr Haematol,Fac Med, London, England
来源：
HAEMATOLOGICA | 2020年 / 105卷 / 05期
关键词：
MOLECULAR RESPONSE; CLINICAL-PRACTICE; INHIBITORS; IMATINIB; DISCONTINUATION; RECOMMENDATIONS; GUIDELINES; DASATINIB;
D O I：
10.3324/haematol.2019.234179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E225 / E227
页数：3
相关论文
共 50 条
  • [31] Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations
    Razga, Filip
    Jurcek, Tomas
    Zackova, Daniela
    Dvorakova, Dana
    Toskova, Martina
    Jeziskova, Ivana
    Mayer, Jiri
    Racil, Zdenek
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (04) : 251 - 259
  • [32] Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype
    Jiang, Xiaoyan
    Grant, Hannah
    Stebbing, Justin
    Foroni, Letizia
    Craddock, Charles
    Griffiths, Mike
    Clark, Richard E.
    O'Brien, Stephen
    Khorashad, Jamshid S.
    Gerrard, Gareth
    Wang, Lihui
    Irving, Julie
    Wang, Meng
    Karran, Loraine
    Dyer, Martin J. S.
    Forrest, Donna L.
    Page, Karen
    Eaves, Connie J.
    Woolfson, Adrian
    BLOOD, 2010, 116 (21) : 1390 - 1391
  • [33] E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
    Claudiani, Simone
    Apperley, Jane F.
    Gale, Robert Peter
    Clark, Richard
    Szydlo, Richard
    Deplano, Simona
    Palanicawandar, Renuka
    Khorashad, Jamshid
    Foroni, Letizia
    Milojkovic, Dragana
    HAEMATOLOGICA, 2017, 102 (08) : E297 - E299
  • [34] Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients
    Sanchez, Ricardo
    Ayala, Rosa
    Carreno Gomez-Tarragona, Gonzalo
    Maria Jose, Espino
    Cuevas, Beatriz
    Raul, Vanegas
    Casado Montero, Luis Felipe
    Garcia-Ormena, Nuria
    Angel Hernandez, Jose
    Bravo, Pilar
    Seri, Cristina
    Anguita, Eduardo
    Barragan, Eva
    Ferrer Marin, Francisca
    Dolores Monteagudo, Maria
    Jorge, Sanchez-Calero
    Sevilla, Julian
    Ruiz, Elena
    Villalon, Lucia
    Del Mar Herraez, Maria
    Riaza, Rosalia
    Magro, Elena
    Luis Steegmann, Juan
    Garcia Gutierrez, Valentin
    Martinez-Lopez, Joaquin
    BLOOD, 2019, 134
  • [35] GENETIC MUTATIONS OUTSIDE BCR-ABL1 DETERMINING TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA
    Aref, Salah
    Abdalla, Nada
    Muller, Martin
    El Sharaway, Solofa
    Aziz, Sherin Abdel
    Sauselle, Sussane
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 : 17 - 17
  • [36] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors
    Kihel, I.
    Nachi, M.
    Cayuela, J.
    Bekadja, M. A.
    Note, A.
    CLINICA CHIMICA ACTA, 2024, 558
  • [37] Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib
    Golale Rostami
    Mohammad Hamid
    Majid Yaran
    Mohsen Khani
    Morteza Karimipoor
    Journal of Human Genetics, 2015, 60 : 253 - 258
  • [38] Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib
    Rostami, Golale
    Hamid, Mohammad
    Yaran, Majid
    Khani, Mohsen
    Karimipoor, Morteza
    JOURNAL OF HUMAN GENETICS, 2015, 60 (05) : 253 - 258
  • [39] Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
    Fominykh, Mikhail
    Shuvaev, Vasily
    Martynkevich, Irina
    Shukhov, Oleg
    Chelysheva, Ekaterina
    Turkina, Anna G.
    Abdulkadyrov, Kudrat
    BLOOD, 2016, 128 (22)
  • [40] Detection of BCR/ABL kinase domain mutations in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment.
    Chu, S
    Snyder, DS
    Sawyers, C
    Forman, SJ
    Bhatia, R
    BLOOD, 2003, 102 (11) : 70A - 71A
12345